vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin
HIGH POINT, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-...
What is the potential impact on VTVT’s stock volatility and trading volume in the short term following the announcement?
How might the market react to the sentiment score of 70 and the overall positive tone of the release?
Will the patent allowance trigger any milestone payments or trigger clauses in existing collaborations or financing agreements?
13 days ago